ChromaDex (NASDAQ:CDXC) Stock, Quote.Headers.trade-ideas

ChromaDex

ChromaDex Corp is a bioscience company dedicated to healthy aging. It is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. The company is the innovator behind NAD+ precursor nicotinamide riboside (NR), commercialized as the flagship ingredient Niagen. The company has three reportable segments namely Consumer Products, Ingredients segment, and Analytical Reference Standards and Services. The majority of the revenue is earned from the Consumer Products segment.

Penang,,Malaysia,-,Feb,2,,2021:,Gamestop,Corp,Sign,Is

News

Intraday Update

Markets

Movers

Trading Ideas

AMSWA

AONC

ASNS

ASXC

BBCP

BGXX

BMEA

BNED

BRZE

CDXC

CEA INDUSTRIES INC by CEA Industries Inc.

CEAD

CLEU

DOCU

FFIE

GERN

GRRR

LFLY

MAIA

MCRB

MITQ

MLGO

NVAX

PRST

SCNI

SIFY

SMTC

SPWR

TPHS

UPST

VERO

VLCN

YEXT

Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday&#39;s Mid-Day Session

Penny Stocks

Small Cap

Pre-Market Outlook

AAON

ADAP

AGRX

AKYA

ALLK

ALTO

APPH

ARQQ

ARVL

ATHX

ATIP

ATRO

AVCO

BRMK

CGTX

CLAR

COIN

CTIC

DBGI

DOCN

EHTH

EOSE

FGEN

FIVN

FSRD

GAIA

GRPN

GRWG

GSUN

HAIN

Hims & Hers Health, Inc. Class A Common Stock

HIMS

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

HOOD

HUDI

ICCM

LITE

LPSN

LPTX

LTRPA

LYFT

LYLT

MAPS

METC

MLNK

MPLN

MRNS

MSTR

NCLH

NCMI

NRBO

NSTG

OABI

OCUL

OCUP

ONCS

ONCY

OPRT

PKBO

PLNT

PNTG

PRGO

PRTY

RETA

ROVR

SEDG

SIBN

SKYT

SLNA

TASK

TCMD

TRIP

TRUE

TTWO

UFAB

VORB

VRTV

XELA

XXII

YMAB

Gainers


	Unique Fabricating, Inc. (NYSE: UFAB) jumped 56.3% to close at $0.8205 on Tuesday. Unique Fabricating posted a Q3 loss of $0.90 per share after the closing bell on Tuesday.


Why Party City Holdco Shares Tumbled Over 40%; Here Are 98 Biggest Movers From Yesterday

Lordstown Motors Corp. - Class A Common Stock

RIDE

TNYA

TWOU

Gainers


	IceCure Medical Ltd (NASDAQ: ICCM) shares jumped 39.4% to $1.4529 after the company announced a payment assignment from the Centers for Medicare &amp; Medicaid Services for the ProSense breast cancer cryoablation procedures.


Why TaskUs Shares Are Trading Higher By 37%? Here Are 77 Stocks Moving In Tuesday&#39;s Mid-Day Session

ChromaDex Corp

Results from the at-home test kit are available to HCPs and their patients through 1health
<a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fwww.chromadex.com%2F&amp;esheet=54097998&amp;newsitemid=20240723490080&amp;lan=en-US&amp;anchor=ChromaDex+Corp.&amp;index=1&amp;md5=4de4481c5a75166f25ee8bc8e2c9a780">ChromaDex Corp.</a> (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>), the global authority on nicotinamide adenine dinucleotide (NAD+) research with a focus on healthy aging, launches the <a href="https://cts.businesswire.com/ct/CT?id=smartlink&amp;url=https%3A%2F%2Fpro.truniagen.suitestore.dev%2Fniagen-plus-nad-plus-test-kit&amp;esheet=54097998&amp;newsitemid=20240723490080&amp;lan=en-US&amp;anchor=Niagen%2B+NAD%2B+Test+Kit&amp;index=2&amp;md5=39712b02001adc939e35c1ed5892f5e5">Niagen+ NAD+ Test Kit</a>&#x2A;, now available exclusively through the company's healthcare practitioner (HCP) channel. This innovative test kit provides practitioners with a reliable method for measuring patient blood NAD+ levels, helping them create more personalized and effective patient protocols using ChromaDex's NAD+-boosting HCP products, Tru Niagen&#xAE; and Niagen+.

Biotech

General

ChromaDex Launches Niagen+ NAD+ Test Kit Available Exclusively To Health Care Practitioners

Management

Chromadex Says Board Appointed James Lee As Interim CFO

U.S. FDA-registered 503B outsourcing facility, Wells Pharma of Houston, will compound and distribute Niagen (nicotinamide riboside chloride) IV and injections to Cenegenics, Clean Market/NutriDrip, Drip Hydration, EXTEN IV, Kensho Wellbeing, The NAD MD, Next Health, The Remedy Room, Restore Hyper Wellness, and REVIV

ChromaDex To Ship Pharmaceutical-Grade Intravenous and Injectable Niagen At Wellness Clinics In August

HC Wainwright &amp; Co. analyst Raghuram Selvaraju reiterates ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) with a Buy and maintains $6 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on ChromaDex, Maintains $6 Price Target

ChromaDex Joins Russell 2000 Index As Part Of Annual Reconstitution; Inclusion Effective July 1, 2024

NR improved the six-minute walking distance and treadmill walking time for those with PAD

Milestone Phase II Clinical Study Demonstrates Niagen Patented Nicotinamide Riboside To Improve Functional Mobility For Individuals With Peripheral Artery Disease

ChromaDex Unveils Niagen+ With FDA Authorization; NRC To Be Available In IV, Shot, And Push Forms At Clinics Nationwide

Roth MKM analyst Sean McGowan maintains ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) with a Buy and maintains $6 price target.

Roth MKM Maintains Buy on ChromaDex, Maintains $6 Price Target

Shares of GameStop Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GME#NYSE">GME</a>) fell sharply during Friday's session after the company released worse-than-expected first-quarter results before schedule and filed to <a href="https://www.benzinga.com/news/earnings/24/06/39224137/gamestop-releases-q1-results-ahead-of-roaring-kitty-event-files-prospectus-to-raise-capital-via-equ">sell up to 75 million shares</a>.
GameStop released its first-quarter 2024 results early Friday ahead of its scheduled June 11 date. The company reported net sales of $881.8 million, down from $1.237 billion year-over-year. The net sales total missed a consensus estimate of $995.3 million. The company reported a loss of 12 cents per share, missing the estimate of a loss of 9 cents per share, according to data from <a href="https://pro.benzinga.com/dashboard">Benzinga Pro</a>.
GameStop shares dipped 22.5% to $36.07 on Friday.
Here are some other stocks moving in today&#8217;s mid-day session.
<h3 class="wp-block-heading">Gainers</h3>
<ul>
<li>Trinity Place Holdings Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TPHS#NYSE">TPHS</a>) jumped 165.4% to $0.3220 after declining around 11% on Thursday.</li>
<li>Leafly Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LFLY#NASDAQ">LFLY</a>) shares gained 91.6% to $3.87.</li>
<li>Venus Concept Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VERO#NASDAQ">VERO</a>) shares jumped 87.5% to $1.1606 on continued upward momentum after the stock regained Nasdaq compliance.</li>
<li>Asensus Surgical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASXC#NASDAQ">ASXC</a>) climbed 40.1% to $0.3291 after the company announced it will be acquired by KARL STORZ for $0.35 per share in cash.</li>
<li>Faraday Future Intelligent Electric Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FFIE#NASDAQ">FFIE</a>) gained 29.3% to $0.7032.</li>
<li>Geron Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GERN#NASDAQ">GERN</a>) shares jumped 26% to $4.90 as the company reported the FDA approval of RYTELO&#x2122; (imetelstat), a first-in-class telomerase inhibitor, for the treatment of adult patients with lower-risk MDS with transfusion-dependent anemia.</li>
<li>China Liberal Education Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLEU#NASDAQ">CLEU</a>) gained 23.4% to $2.4899.</li>
<li>American Oncology Network, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AONC#NASDAQ">AONC</a>) gained 22.6% to $2.0850. American Oncology Network recently announced the opening of Low Country Radiation in Waycross, Georgia.</li>
<li>MAIA Biotechnology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAIA#NASDAQ">MAIA</a>) rose 21.2% to $4.0249. The company unveiled compelling efficacy data from its Phase 2 THIO-101 clinical trial.</li>
<li>ChromaDex Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) gained 19.2% to $3.41 after the company received exclusive FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Nicotinamide Riboside Chloride in the treatment of Ataxia Telangiectasia.</li>
<li>SunPower Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SPWR#NASDAQ">SPWR</a>) rose 18.8% to $4.11.</li>
<li>Oddity Tech Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ODD#NASDAQ">ODD</a>) gained 18.3% to $43.49 after the company approved a share buyback and raised its Q2 guidance.</li>
<li>Universe Pharmaceuticals INC (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPC#NASDAQ">UPC</a>) jumped 14.3% to $2.64</li>
<li>Presto Automation Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRST#NASDAQ">PRST</a>) rose 14.1% to $0.0866 after declining 27% on Thursday.</li>
<li>Yext, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/YEXT#NYSE">YEXT</a>) gained 14.7% to $5.42. Yext is said to hire investment bankers to explore strategic alternatives, including a sale, Reuters reported.</li>
<li>Argan, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGX#NYSE">AGX</a>) jumped 11.1% to $76.78 after the company reported better-than-expected first-quarter financial results.</li>
<li>Planet Labs PBC (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PL#NYSE">PL</a>) gained 9.6% to $1.9950 following better-than-expected quarterly earnings.</li>
<li>Braze, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRZE#NASDAQ">BRZE</a>) rose 4.2% to $38.32 following better-than-expected first-quarter earnings.</li>
</ul>
<h3 class="wp-block-heading">Losers</h3>
<ul>
<li>Biomea Fusion, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BMEA#NASDAQ">BMEA</a>) shares dipped 65.6% to $3.87 after the United States Food and Drug Administration (FDA) imposed a full clinical hold on its Phase I/II trials for BMF-219, a diabetes treatment.</li>
<li>Barnes &amp; Noble Education, Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BNED#NYSE">BNED</a>) fell 35.3% to $0.2101 after the company announced final results of rights offering.</li>
<li>Scinai Immunotherapeutics Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SCNI#NASDAQ">SCNI</a>) fell 31.3% to $2.7474. Scinai Immunotherapeutics regained compliance with Nasdaq minimum bid price requirement.</li>
<li>Volcon, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VLCN#NASDAQ">VLCN</a>) fell 29.3% to $9.90. Volcon recently announced a 1-for-100 reverse stock split.</li>
<li>Latam Logistic Properties, S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LPA#NYSE">LPA</a>) shares fell 26.4% to $34.69 after jumping 49% on Thursday.</li>
<li>Hywin Holdings Ltd. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HYW#NYSE">HYW</a>) dipped 24.7% to $0.4670.</li>
<li>MicroAlgo Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MLGO#NASDAQ">MLGO</a>) shares fell 24.2% to $4.24. MicroAlgo recently announced that it entered into convertible note purchase agreements with certain investors.</li>
<li>Actelis Networks, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ASNS#NASDAQ">ASNS</a>) dipped 23% to $1.5101. Actelis announced closing of exercise of warrants for $3 million gross proceeds.</li>
<li>Semtech Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SMTC#NASDAQ">SMTC</a>) dipped 19.6% to $30.54 after the company announced it has appointed a new President and CEO and reaffirmed Q2 2025 guidance.</li>
<li>Gorilla Technology Group Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRRR#NASDAQ">GRRR</a>) fell 19.3% to $4.7699 after announcing a $12 million registered direct offering.</li>
<li>Bright Green Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BGXX#NASDAQ">BGXX</a>) shares fell 18.7% to $0.2851 after declining around 8% on Thursday.</li>
<li>Seres Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCRB#NASDAQ">MCRB</a>) declined 18.7% to $0.6916. Canaccord Genuity analyst John Newman maintained Seres Therapeutics with a Buy and lowered the price target from $15 to $10.</li>
<li>CEA Industries Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CEAD#NASDAQ">CEAD</a>) dipped 18% to $6.65.</li>
<li>Oil-Dri Corporation of America (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ODC#NYSE">ODC</a>) fell 17.3% to $68.57 following third-quarter results.</li>
<li>mF International Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MFI#NASDAQ">MFI</a>) fell 17.1% to $1.07.</li>
<li>Vail Resorts, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTN#NYSE">MTN</a>) shares declined 13.6% to $167.50 after the company reported weaker-than-expected results for its third quarter on Thursday.</li>
<li>Samsara Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IOT#NYSE">IOT</a>) shares dipped 13.4% to $30.17 after the company reported first-quarter earnings.</li>
<li>Moving iMage Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MITQ#NYSE">MITQ</a>) fell 10.3% to $0.6001 after declining 33% on Thursday. Moving iMage Technologies was recently awarded a multi-million dollar contract.</li>
<li>Novavax, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVAX#NASDAQ">NVAX</a>) declined 10.2% to $17.56.</li>
<li>Sify Technologies Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SIFY#NASDAQ">SIFY</a>) fell 10.1% to $0.8001 as the company announced commencement of its previously announced rights offering.</li>
<li>Harmony Gold Mining Company Limited (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HMY#NYSE">HMY</a>) fell 9.2% to $8.36. Shares of precious metals companies traded lower amid a decline in gold and silver following US economic data.</li>
<li>Concrete Pumping Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BBCP#NASDAQ">BBCP</a>) shares dipped 8% to $6.93 after posting weaker-than-expected second-quarter results.</li>
<li>Upstart Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UPST#NASDAQ">UPST</a>) tumbled 8% to $24.75.</li>
<li>American Software, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMSWA#NASDAQ">AMSWA</a>) declined 7.5% to $9.55 following quarterly results. B. Riley Securities analyst Zach Cummings maintained American Software with a Buy and lowered the price target from $16 to $14.</li>
<li>DocuSign, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DOCU#NASDAQ">DOCU</a>) shares fell 7.4% to $50.57. DocuSign reported better-than-expected earnings for its first quarter and the company&#8217;s board also authorized a $1 billion increase to its existing stock repurchase program. The company said it sees second-quarter billings in the range of $715 million to $725 million.</li>
<li>Impinj, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PI#NASDAQ">PI</a>) fell 7.1% to $153.03.</li>
<li>Gen Digital Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GEN#NASDAQ">GEN</a>) declined 5.2% to $24.13 after Morgan Stanley downgraded the stock from Overweight to Equal-Weight and lowered its price target from $28 to $27.</li>
</ul>
Now Read This: <a href="https://www.benzinga.com/news/24/06/39226995/over-2m-bet-on-this-tech-stock-check-out-these-4-stocks-insiders-are-buying">Over $2M Bet On This Tech Stock? Check Out These 4 Stocks Insiders Are Buying</a>

Why GameStop Shares Are Trading Lower By Over 22%? Here Are Other Stocks Moving In Friday's Mid-Day Session

WIIM

ChromaDex shares are trading higher after the company received exclusive FDA Orphan Drug Designation and Rare Pediatric Disease Designation for Nicotinamide Riboside Chloride in the treatment of Ataxia Telangiectasia.

ChromaDex Announces FDA Orphan Drug And Rare Pediatric Disease Designations For NRC In Treatment Of Ataxia Telangiectasia (AT)

<a href="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1004624" title="https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1004624">https://www.accessdata.fda.gov/scripts/opdlisting/oopd/detailedIndex.cfm?cfgridkey=1004624</a>

ChromaDex Gets Orphan Designation Status From FDA For Nicotinamide Riboside Chloride For Treatment Of Ataxia Telangiectasia

<h3>Gainers</h3>
<ul>
<li>CytomX Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTMX#NASDAQ">CTMX</a>) stock increased by 87.1% to $7.84 during Wednesday's after-market session. The market value of their outstanding shares is at $534.1 million. As per the press release, Q1 earnings came out today. </li>
<li>ZimVie (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZIMV#NASDAQ">ZIMV</a>) shares increased by 17.03% to $18.0. The company's market cap stands at $489.9 million. The company's, Q1 earnings came out today. </li>
<li>Aesthetic Medical Intl (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AIH#NASDAQ">AIH</a>) shares moved upwards by 15.0% to $0.53. The market value of their outstanding shares is at $25.2 million. </li>
<li>electroCore (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECOR#NASDAQ">ECOR</a>) shares rose 11.98% to $7.85. The market value of their outstanding shares is at $47.1 million. The company's, Q1 earnings came out today. </li>
<li>Ventyx Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VTYX#NASDAQ">VTYX</a>) shares rose 10.81% to $4.92. The company's market cap stands at $346.8 million. </li>
<li>Alzamend Neuro (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALZN#NASDAQ">ALZN</a>) stock increased by 9.82% to $0.58. The market value of their outstanding shares is at $3.9 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Etao International Co (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ETAO#NASDAQ">ETAO</a>) shares decreased by 14.1% to $1.64 during Wednesday's after-market session. The market value of their outstanding shares is at $8.4 million. </li>
<li>Enhabit (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EHAB#NYSE">EHAB</a>) stock decreased by 13.1% to $8.43. The market value of their outstanding shares is at $422.8 million. As per the press release, Q1 earnings came out today. </li>
<li>Myomo (AMEX:<a class="ticker" href="https://www.benzinga.com/stock/MYO#AMEX">MYO</a>) stock decreased by 10.69% to $3.51. The company's market cap stands at $101.0 million. The company's, Q1 earnings came out today. </li>
<li>Exact Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/EXAS#NASDAQ">EXAS</a>) shares decreased by 10.11% to $53.47. The market value of their outstanding shares is at $9.8 billion. As per the press release, Q1 earnings came out today. </li>
<li>Outset Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OM#NASDAQ">OM</a>) shares declined by 8.25% to $3.79. The market value of their outstanding shares is at $195.9 million. As per the press release, Q1 earnings came out today. </li>
<li>ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) shares decreased by 6.79% to $3.57. The market value of their outstanding shares is at $269.6 million. The company's, Q1 earnings came out today. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

ALZN

CTMX

ECOR

EHAB

ETAO

EXAS

VTYX

ZIMV

12 Health Care Stocks Moving In Wednesday's After-Market Session

ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) reported quarterly losses of $(0.01) per share which beat the analyst consensus estimate of $(0.02) by 50 percent. The company reported quarterly sales of $22.200 million which missed the analyst consensus estimate of $23.970 million by 7.38 percent. This is a 1.58 percent decrease over sales of $22.556 million the same period last year.

Earnings

Earnings Beats

Earnings Misses

ChromaDex Q1 2024 Adj EPS $(0.01) Beats $(0.02) Estimate, Sales $22.200M Miss $23.970M Estimate

ChromaDex Announces Ingredient Partnership With Solgar; Solgar Cellular Nutrition Cellular Energy Features NIAGEN To Support NAD+ Levels For Cellular Health

Tru Niagen is now available at 700 retail locations of The Vitamin Shoppe and Super Supplements&#x2122; and online at vitaminshoppe.com

ChromaDex Launches Tru Niagen At The Vitamin Shoppe

ChromaDex Announces That Its Flagship Product, Tru Niagen Is Now Available At Sprouts Farmers Market, Marking Its Inaugural Major Grocery Debut

Roth MKM analyst Sean McGowan maintains ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) with a Buy and raises the price target from $4.25 to $6.

Roth MKM Maintains Buy on ChromaDex, Raises Price Target to $6

<h3>Gainers</h3>
<ul>
<li>Fresh2 Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FRES#NASDAQ">FRES</a>) shares rose 41.7% to $0.66 during Monday's regular session. The market value of their outstanding shares is at $15.7 million. </li>
<li>Akso Health Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AHG#NASDAQ">AHG</a>) stock moved upwards by 29.0% to $1.29. The company's market cap stands at $141.3 million. </li>
<li>ChromaDex (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CDXC#NASDAQ">CDXC</a>) stock moved upwards by 27.91% to $3.07. The company's market cap stands at $231.1 million. </li>
<li>Elicio Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELTX#NASDAQ">ELTX</a>) stock moved upwards by 24.0% to $6.2. The market value of their outstanding shares is at $59.5 million. </li>
<li>Immuneering (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IMRX#NASDAQ">IMRX</a>) stock increased by 23.04% to $2.35. The company's market cap stands at $68.8 million. </li>
<li>Biotricity (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BTCY#NASDAQ">BTCY</a>) stock rose 21.08% to $1.55. The company's market cap stands at $14.5 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>Trxade Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MEDS#NASDAQ">MEDS</a>) shares declined by 33.0% to $19.3 during Monday's regular session. The market value of their outstanding shares is at $23.2 million. </li>
<li>Envoy Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COCH#NASDAQ">COCH</a>) shares declined by 27.6% to $3.62. The market value of their outstanding shares is at $70.7 million. </li>
<li>CareMax (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMAX#NASDAQ">CMAX</a>) shares decreased by 25.28% to $4.14. The market value of their outstanding shares is at $15.5 million. The company's, Q4 earnings came out today. </li>
<li>Titan Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TTNP#NASDAQ">TTNP</a>) shares fell 18.34% to $7.59. The market value of their outstanding shares is at $5.7 million. </li>
<li>Cargo Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRGX#NASDAQ">CRGX</a>) stock declined by 17.67% to $25.75. The company's market cap stands at $1.0 billion. </li>
<li>Molecular Templates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MTEM#NASDAQ">MTEM</a>) shares fell 17.28% to $2.27. The market value of their outstanding shares is at $12.2 million. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BTCY

CMAX

Envoy Medical, Inc. - Class A Common Stock

COCH

CRGX

ELTX

FRES

IMRX

MEDS

MTEM

TTNP

12 Health Care Stocks Moving In Monday's Intraday Session

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
ChromaDex (NASDAQ:<a href="https://investorplace.com/stock-quotes/cdxc-stock-quote/">CDXC</a>) just reported results for the first quarter of 2024.<ul><li>ChromaDex reported earnings per share of -1 cent. This was above the analyst estimate for EPS of -2 cents.</li><li>The company reported revenue of $22.15 million.</li><li>This was 7.58% worse than the analyst estimate for revenue of $23.97 million.</li></ul><div>InvestorPlace Earnings is a project that leverages data from <a href="https://www.tradesmith.com">TradeSmith</a> to automate coverage of quarterly earnings reports. InvestorPlace Earnings distills key takeaways including earnings per share and revenue, as well as how a company stacks up to analyst estimates. These articles are published without human intervention, allowing us to inform our readers of the latest figures as quickly as possible. To report any concerns or inaccuracies, please contact us at <a href="mailto:editor@investorplace.com">editor@investorplace.com</a>.</div><h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT802110">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
																<li>
						<a href="https://investorplace.com/2024/04/legendary-investor-predicts-forget-a-i-this-technology-is-the-future/?cid=MKT794457&amp;eid=MKT802109">Legendary Investor Predicts: &ldquo;Forget A.I. THIS Technology Is the Future&rdquo;</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/earning-results/2024/05/cdxc-stock-earnings-chromadex-for-q1-of-2024/">CDXC Stock Earnings: ChromaDex Beats EPS, Misses Revenue for Q1 2024</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

CDXC Stock Earnings: ChromaDex Beats EPS, Misses Revenue for Q1 2024

ChromaDex shares jump 9% on FDA designations for NRC

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on High Tide (HITI – Research Report), Ultragenyx Pharm...

Analysts Are Bullish on These Healthcare Stocks: High Tide (HITI), Ultragenyx Pharmaceutical (RARE)

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

The Only Monthly Membership With a Positive ROI!

-

-

-

-

-

-

-

Comments

ChromaDex

ChromaDex (CDXC) Forecast

ChromaDex (NASDAQ:CDXC) Stock, Quote.Headers.trade-ideas